Advancing mRNA Therapeutics: Lipid Nanoparticles Demonstrate Favorable Safety And Efficacy Profile With Repeated mRNA Administration In Normal And Tumor Bearing Mice

By Sams M. A. Sadat, Leanna Yee, Zhengyu Chen, Kalyan Golla, Tony Wu, Vicente Lacap, Richard Jiang, Jay Paquette, Malathi Anantha, Noor Aibani, Nikita Jain, and Anitha Thomas

Can mRNA-LNP formulations remain safe and effective through repeated administration? Researchers evaluated multiple formulations in mice across as many as nine doses, administered at 21-day intervals over approximately six months. The analysis tracked clinical observations, liver enzymes, inflammatory markers, anti-PEG antibodies, and antigen-specific immune responses to build a detailed picture of repeat-dose performance. Novel LNP formulations were associated with minimal adverse events and no indications of systemic toxicity. In a melanoma mouse model, a lead formulation also demonstrated antitumor effects following four repeated doses.

Delve into the findings to better understand how LNP composition may influence tolerability, immune response, and therapeutic potential in mRNA applications requiring sustained treatment or long-term immunization.